Year All202620252024202320222021202020192018 Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 September 18, 2025 Contineum Therapeutics to Present at September Investor Conferences August 28, 2025 Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones August 5, 2025 Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 June 25, 2025 Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference May 15, 2025 Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones May 14, 2025 Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development April 28, 2025 Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors March 17, 2025 Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum March 12, 2025 Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones March 6, 2025
Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 September 18, 2025
Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones August 5, 2025
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791 June 25, 2025
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference May 15, 2025
Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones May 14, 2025
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development April 28, 2025
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors March 17, 2025
Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones March 6, 2025
Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
Contineum Therapeutics to Present at September Investor Conferences
Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference
Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum
Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones